ChangeBridge: EPO Bulletin - Therapeutics (A61P)

EPO Patent: Tetrahydrocyclopentyl Pyrrole Derivative Preparation and Use

The European Patent Office has published patent application EP4635949A1 concerning the preparation and use of a substituted tetrahydrocyclopentyl pyrrole derivative. The patent application lists Jiangsu NHWA Pharmaceutical Co., Ltd as the applicant and details various inventors.

EPO Patent Granted for Proximod Crystal Form

The European Patent Office has granted a patent (EP4635945A1) for a crystal form of Proximod, its preparation method, and its use. The patent was published on March 18, 2026, with applicants Jiankuan (Suzhou) Biotechnology Co., Ltd and the Institute of Materia Medica, Chinese Academy of Medical Sciences.

EPO Patent for Bispecific Fusion Protein Targeting TNF-α and IL-17A

The European Patent Office has published patent application EP4635988A1 for a bispecific fusion protein targeting TNF-α and IL-17A, filed by Jiangsu Kanion Pharmaceutical Co., Ltd. The patent is related to therapeutic uses for conditions such as inflammation and autoimmune diseases.

Novel Biaryl Ring Compound as Immunomodulator Patent Application

The European Patent Office has published a patent application (EP2024125662A1) by Shanghai Longwood Biopharmaceuticals Co., Ltd. for a novel biaryl ring compound described as an immunomodulator. The application details the preparation and application of this compound, with designated states including most European countries.

EPO Patent Filing for Sickle Cell Disease Treatment

The European Patent Office has published a patent application filed by BioLineRx Ltd. and The Washington University for a treatment of sickle cell disease. The patent, designated EP4630032A1, was published on March 18, 2026.